Literature DB >> 29655277

Interprofessional, psycho-social intervention to facilitate resilience and reduce supportive care needs for patients with cancer: Results of a noncomparative, randomized phase II trial.

Manuela Eicher1,2, Karin Ribi1,3, Catherine Senn-Dubey2, Stefanie Senn2, Pierluigi Ballabeni1, Daniel Betticher4.   

Abstract

OBJECTIVE: We developed 2 intensity levels of a complex intervention for interprofessional supportive care in cancer (IPSC-C) to facilitate resilience and reduce unmet supportive care needs. We aimed to test the feasibility, acceptability, and preliminary effectiveness of both intensity levels in routine practice.
METHODS: In a randomized, noncomparative phase II trial, newly diagnosed patients received either low (LI-IPSC-C) or high (HI-IPSC-C) intensity interventions. Low-intensity-interprofessional supportive care in cancer (LI-IPSC-C) consisted of 3 electronic assessments of resilience, unmet supportive care needs, mood, and coping effort over 16 weeks with an immediate feedback to clinicians including tailored intervention recommendations to facilitate resilience and supportive care. High-intensity-interprofessional supportive care in cancer (HI-IPSC-C) added 5 structured consultations (face-to-face and telephone) provided by specialized nurses. Primary outcome was a change ≥5 in resilience score on the Connor-Davidson Resilience Scale (CD-RISC). Secondary outcomes were unmet supportive care needs, mood, and coping effort. We assessed feasibility by clinician-provided tailored interventions as recommended and acceptability through qualitative interviews with clinicians and patients.
RESULTS: In the LI-IPSC-C arm, 11 of 41, in the HI-IPSC-C arm 17 of 43, patients increased resilience scores by ≥5. Relatively more patients decreased unmet needs in HI-IPSC-C arm. Mood, in both arms, and coping effort, in HI-IPSC-C arm, improved meaningfully. Feasibility was limited for the LI-IPSC-C arm, mainly due to lack of time; acceptability was high in both arms.
CONCLUSION: Neither LI-IPSC-C nor HI-IPSC-C interventions reached the desired threshold. HI-IPSC-C showed positive effects on secondary outcomes and was feasible. Resilience as measured by the CD-RISC may not be the optimal outcome measure for this intervention.
Copyright © 2018 John Wiley & Sons, Ltd.

Entities:  

Keywords:  cancer; complex intervention; interprofessional supportive care; nursing; oncology; resilience; supportive care needs

Mesh:

Year:  2018        PMID: 29655277     DOI: 10.1002/pon.4734

Source DB:  PubMed          Journal:  Psychooncology        ISSN: 1057-9249            Impact factor:   3.894


  4 in total

1.  Association of resilience with health-related quality of life and depression in multiple myeloma and its precursors: results of a German cross-sectional study.

Authors:  Imad Maatouk; Susanne He; Natalia Becker; Manuela Hummel; Stefan Hemmer; Michaela Hillengass; Hartmut Goldschmidt; Mechthild Hartmann; Dieter Schellberg; Wolfgang Herzog; Jens Hillengass
Journal:  BMJ Open       Date:  2018-07-30       Impact factor: 2.692

2.  Effects of cognitive behavioral therapy on psychological adjustment in Chinese pediatric cancer patients receiving chemotherapy: A randomized trial.

Authors:  Ping Zhang; Lin Mo; Joseph Torres; Xiaoyan Huang
Journal:  Medicine (Baltimore)       Date:  2019-07       Impact factor: 1.817

3.  Protocol for 'Resilient Caregivers': a randomised trial of a resilience-based intervention for psychologically distressed partner caregivers of patients with cancer.

Authors:  Peter Genter; Beverley Lim Høeg; Camilla Jensen Hamre; Elisabeth Anne Wreford Andersen; Susanne Oksbjerg Dalton; Bjørn Ribers; Pernille Envold Bidstrup
Journal:  BMJ Open       Date:  2021-11-12       Impact factor: 2.692

4.  Towards a novel approach guiding the decision-making process for anticancer treatment in patients with advanced cancer: framework for systemic anticancer treatment with palliative intent.

Authors:  K Ribi; N Kalbermatten; M Eicher; F Strasser
Journal:  ESMO Open       Date:  2022-05-18
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.